

## Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Pharmascience Inc. and Teva Canada Limited that the shortages of pms-Salbutamol Polyneb 22 mg/ml Inhalation Unit Dose Solution (DIN 02208237) and Teva-Salbutamol Sterinebs P.F. 2 mg/ml Inhalation Unit Dose Solution (DIN 02173360) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 15, 2016**.

### SALBUTAMOL SULFATE

#### 2 MG / ML (BASE) INHALATION UNIT DOSE SOLUTION

00002208237	PMS-SALBUTAMOL POLYNEB	PMS	\$ 0.2748
00002173360	TEVA-SALBUTAMOL STERINEBS P.F.	TEV	\$ 0.2748
00002239366	RATIO-SALBUTAMOL UNI DOSE P.F.	RPH	\$ 0.2885
00002213427	VENTOLIN NEBULES P.F.	GSK	\$ 0.7970

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Quinapril 40 mg Tablet (DIN 02248502) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

### QUINAPRIL

#### 40 MG (BASE) ORAL TABLET

00002248502	APO-QUINAPRIL	APX	\$ 0.6867
00001947699	ACCUPRIL	PFI	\$ 0.9238

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Prazo 1 mg Tablet (DIN 00882801) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

### PRAZOSIN HCL

#### 1 MG (BASE) ORAL TABLET

00000882801	APO-PRAZO	APX	\$ 0.2743
00001934198	TEVA-PRAZOSIN	TEV	\$ 0.2766

... continued from previous page

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Prazo 2 mg Tablet (DIN 00882828) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

#### PRAZOSIN HCL

##### 2 MG (BASE) ORAL TABLET

00000882828	APO-PRAZO	APX	\$ 0.3725
00001934201	TEVA-PRAZOSIN	TEV	\$ 0.3825

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Prazo 5 mg Tablet (DIN 00882836) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 16, 2016**.

#### PRAZOSIN HCL

##### 5 MG (BASE) ORAL TABLET

00000882836	APO-PRAZO	APX	\$ 0.5121
00001934228	TEVA-PRAZOSIN	TEV	\$ 0.5259

## Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Rythmol 300 mg Tablet (DIN 00603716) manufactured by BGP Pharma ULC, and Apo-Propafenone 300 mg Tablet (DIN 02243325) manufactured by Apotex Inc., pms-Propafenone 300 mg Tablet (DIN 02294575) manufactured by Pharmascience Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

BGP Pharma ULC has advised Alberta Blue Cross that the shortage Rhythmol 300 mg Tablet (DIN 00603716) has now been resolved. As a result, pms-Propafenone 300 mg Tablet (DIN 02294575) will no longer be considered as a temporary benefit for the *ADBL* **after January 15, 2016**.

---

#### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)  
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

---



\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.568 2015/12